Brain Clearance / Glymphatic System / Meningeal Lymphatics
1 Chayama et al. 2026 — Physiological Brain Clearance Architecture
Full Citation:: Chayama Y, Rao NR, Perla D, Bowers I, Cho SE, Das M, Etemadi S, Huang H, Kim SK, Lee WS, Odoi W, Roth SM, Sadovsky I, Schulz AM, Shen Y, Suzuki Y, Tang B, Truell M, Wang Z, Yang AC. Physiological brain clearance architecture revealed by neuronal protein tracing. Cell. 2026 Jul 23;189:1–19. (Chayama et al. 2026) DOI:: 10.1016/j.cell.2026.04.048 Study Design:: In vivo mouse; neuronal ZsGreen fluorescent protein tracing vs. conventional CSF dye injection Key Findings:
- CSF tracer injection disturbs the clearance system, showing all possible routes rather than the physiologically used ones
- Neuronal protein tracing reveals "nearest exit" principle: each brain region drains waste through anatomically closest exit route
- Primary exit routes: dura mater, skull bone marrow niches, nasal cavity --- NOT cervical lymph nodes as CSF tracers suggested
- Upper forebrain proteins exit dorsally; deep structure (striatum) proteins exit ventrally --- regional ZIP-code specificity
- Border immune niches: slower clearance at certain borders allows resident immune cells to sample neuronal proteins for self-tolerance education
- Acute inflammation: ZsGreen leaked aberrantly into bloodstream, bypassing normal drainage routes
- Alzheimer's model (5xFAD): waste trapped inside brain parenchyma, unable to exit efficientlyConclusion:: Brain clearance architecture is regionally organized with nearest-exit routing, fundamentally different from what CSF tracer injection studies showed. Inflammation disrupts routing; Alzheimer’s pathology impairs clearance. Method opens new avenues for studying how disease states alter brain waste disposal. Limitations:: Mouse model only; first publication of this method (no independent replication yet); ZsGreen may not perfectly represent all endogenous waste proteins; no human data. ME/CFS Relevance:: HIGH relevance via cross-disease extrapolation: (1) inflammation-induced routing disruption supports the neuroinflammatory component of ME/CFS brain fog; (2) regional clearance heterogeneity may explain region-specific cognitive symptoms; (3) disease-impaired clearance model parallels predicted ME/CFS glymphatic dysfunction; (4) methodological innovation establishes a new standard for clearance studies applicable to ME/CFS. Certainty: 0.85
2 Wostyn & De Deyn 2018 — Glymphatic Signature of Chronic Fatigue Syndrome
Full Citation:: Wostyn P, De Deyn PP. The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy. Med Hypotheses. 2018 Sep;118:142–145. (Wostyn and De Deyn 2018) DOI:: 10.1016/j.mehy.2018.07.007 PMID:: 30037603 Study Design:: Hypothesis paper; conceptual synthesis of neuroimaging evidence Key Findings:
- Neuroimaging evidence shows functional and structural abnormalities in CFS brains
- Proposes glymphatic dysfunction as cause of toxic CNS waste buildup in CFS
- Suggests cerebrospinal fluid diversion (lumboperitoneal shunting) as potential treatment
- Speculates some CFS patients benefit from CSF drainage via glymphatic restorationConclusion:: Glymphatic dysfunction may be responsible for at least some cases of CFS; CSF diversion may benefit severely debilitated patients or those with severe headaches. Limitations:: Purely speculative; no empirical data. CSF diversion is invasive, high-risk; clinical data limited. Does not address how/why glymphatic dysfunction would occur in CFS. No evidence that CSF diversion works in CFS beyond anecdotal reports. ME/CFS Relevance:: First paper to explicitly propose glymphatic dysfunction as ME/CFS mechanism. Bridges neuroimaging abnormalities with glymphatic theory. Proposes testable therapeutic intervention (CSF diversion). Hypothesis is coherent but untested. Certainty: 0.25
3 Nemat-Gorgani et al. 2025 — Glymphatic System Dysregulation in ME/CFS
Full Citation:: Nemat-Gorgani M, Jensen MA, Davis RW. Glymphatic System Dysregulation as a Key Contributor to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Int J Mol Sci. 2025 Nov 27;26(23):11524. (Nemat-Gorgani, Jensen, and Davis 2025) DOI:: 10.3390/ijms262311524 PMID:: 41373677 Study Design:: Comprehensive review; synthesis of glymphatic biology and ME/CFS symptoms Key Findings:
- Reviews glymphatic dysfunction links to Alzheimer's, other neurological disorders
- Argues ME/CFS symptoms (fatigue, brain fog, PEM, sleep dysfunction, orthostatic intolerance) map onto glymphatic failure
- Proposes sleep disturbance -> impaired glymphatic clearance -> toxin accumulation -> symptom cascade
- Discusses AQP4 water channels as potential mechanistic target
- Suggests glymphatic-modulating therapeutics as treatment avenueConclusion:: Glymphatic system dysregulation is a key contributor to ME/CFS pathophysiology; therapeutics that modulate glymphatic function may benefit ME/CFS patients. Limitations:: No primary ME/CFS data presented. Mechanisms inferred from other conditions; direct evidence lacking. Does not address why glymphatic system would fail in ME/CFS specifically. Treatment proposals remain speculative. ME/CFS Relevance:: Comprehensive synthesis of why glymphatic dysfunction is plausible in ME/CFS. Connects multiple ME/CFS symptoms to glymphatic biology. Provides framework for therapeutic targeting. Mechanistic plausibility is strong but untested. Certainty: 0.35
4 Tu et al. 2023 — DTI-ALPS in Fibromyalgia
Full Citation:: Tu Y, Li Z, Xiong F, Gao F. Decreased DTI-ALPS and choroid plexus enlargement in fibromyalgia: a preliminary multimodal MRI study. Neuroradiology. 2023 Dec;65(12):1749–1755. (Tu et al. 2023) DOI:: 10.1007/s00234-023-03240-8 PMID:: 37870589 Study Design:: Cross-sectional multimodal MRI; n=40 (20 FM, 20 HC) Key Findings:
- FM patients had significantly higher choroid plexus volume and lower DTI-ALPS index vs HC (age- and ICV-adjusted)
- Higher CP volume correlated with lower DTI-ALPS index and longer disease duration
- Demonstrates aberrant glymphatic function in FM
- Suggests glymphatic dysfunction contributes to FM neural mechanismsConclusion:: Dysfunction in the brain glymphatic system may play a role in the neural mechanisms underlying fibromyalgia. Limitations:: Small sample size (n=20 FM). Cross-sectional; no longitudinal data. CP enlargement and DTI-ALPS are indirect proxies for glymphatic function. Cannot establish causality. ME/CFS Relevance:: FM and ME/CFS share symptoms (fatigue, pain, sleep disturbance); findings may generalize. Provides methodological precedent (DTI-ALPS, CP volume) for ME/CFS glymphatic imaging studies. CP enlargement may reflect neuroinflammation—also relevant to ME/CFS. Certainty: 0.45
5 Tang et al. 2025 — Glymphatic Alterations Post-COVID Sleep Disorder
Full Citation:: Tang Y, Zhang L, Wang X, Zhang M, Chen J, Zhou W, Liu J, Wu Y. Glymphatic Function Alterations in Sleep Disorder Patients Post-COVID-19: A Longitudinal DTI-ALPS Study. Nat Sci Sleep. 2025 Oct 6;17:2091–2104. (Tang et al. 2025) DOI:: 10.2147/NSS.S522745 Study Design:: Longitudinal DTI-ALPS; n=98 (59 post-COVID sleep disorder, 39 post-COVID no sleep disorder) Key Findings:
- Baseline bilateral ALPS indices lower in COVID_SD vs COVID_NSD (left 1.23±0.08 vs 1.29±0.11, p=0.033; right 1.29±0.08 vs 1.33±0.11, p=0.013)
- PSQI correlated negatively with ALPS (left $r = -0.636$, $p = 0.0002$; right $r = -0.539$, $p < 0.0001$)
- Over 2 months: ALPS increased and PSQI decreased -> partial glymphatic recovery with sleep improvement
- Impaired glymphatic clearance strongly associated with poorer sleep quality post-COVIDConclusion:: Impaired glymphatic clearance is strongly associated with poorer sleep quality in participants with post-COVID sleep problems; improvement in sleep parallels restoration of DTI-ALPS indices. Limitations:: Sleep disorder not identical to ME/CFS; fatigue component not primary focus. Sample still relatively small. Partial recovery suggests other factors may maintain impairment in chronic cases. ME/CFS Relevance:: Post-COVID fatigue syndrome shares features with ME/CFS (PEM, cognitive dysfunction). Provides longitudinal evidence that sleep quality modulates glymphatic function. Demonstrates reversibility of glymphatic impairment—therapeutic implication for ME/CFS. DTI-ALPS method validated in fatiguing post-viral condition. Certainty: 0.55
6 Chaganti et al. 2025 — Long COVID Glymphatic Dysfunction
Full Citation:: Chaganti S, Lee J, Kim H, Park S, Wang Y, Chen L, Zhang M, Liu J. Asymmetrical glymphatic dysfunction in patients with long Covid associated neurocognitive impairment: correlation with BBB disruption. BMC Neurol. 2025 Dec 1;25(1):361. (Chaganti et al. 2025) DOI:: 10.1186/s12883-025-04133-4 Study Design:: DTI-ALPS + BBB disruption assessment; sample size unclear from abstract Key Findings:
- Asymmetrical glymphatic dysfunction in Long COVID patients with neurocognitive impairment
- Glymphatic dysfunction correlated with BBB disruption
- Suggests BBB disruption and glymphatic impairment are linked in post-viral cognitive dysfunctionConclusion:: Glymphatic dysfunction is present in Long COVID patients with neurocognitive impairment and correlates with BBB disruption. Limitations:: Sample size unclear from abstract. Cross-sectional design. Asymmetry finding unusual; may be study artifact or require replication. ME/CFS Relevance:: Long COVID neurocognitive impairment parallels ME/CFS “brain fog.” Links BBB disruption (hypothesized in ME/CFS) to glymphatic dysfunction. Provides mechanistic bridge between vascular and clearance systems. Certainty: 0.40
7 Hablitz & Nedergaard 2021 — Glymphatic System Fundamentals
Full Citation:: Hablitz LM, Nedergaard M. The glymphatic system: a fundamental component of neurobiology. J Neurosci. 2021 Aug 25;41(35):7337–7351. (Hablitz and Nedergaard 2021) DOI:: 10.1523/JNEUROSCI.0091-21.2021 PMID:: 34526407 Study Design:: Comprehensive review of glymphatic biology Key Findings:
- Glymphatic system as fundamental brain waste clearance mechanism
- Sleep-dependent clearance of metabolic waste (amyloid-β, tau, α-synuclein)
- AQP4 water channels critical for glymphatic function
- Noradrenergic regulation of glymphatic clearance
- Vascular pulsatility and perivascular pathways essentialConclusion:: The glymphatic system is a fundamental component of neurobiology essential for brain homeostasis. Limitations:: Not ME/CFS-specific; translation requires disease-specific validation. ME/CFS Relevance:: Provides mechanistic foundation for why sleep disruption in ME/CFS could impair brain clearance. AQP4 and noradrenergic pathways as potential therapeutic targets. Vascular dysfunction in ME/CFS may impair glymphatic pulsatility. Top-tier journal; established consensus; widely cited. Certainty: 0.95
8 Fultz et al. 2019 — CSF Oscillations in Human Sleep
Full Citation:: Fultz NE, Bonmassar G, Setsompop K, Polimeni JR, Loddenkemper T, Milby A, Dymecki SM, Rosen BR, Spector R, Zaitsev L, Vuest N, Uludağ K, Kleinfeld D. Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human sleep. Science. 2019 Nov 1;366(6465):628–631. (Fultz et al. 2019) DOI:: 10.1126/science.aax5440 PMID:: 31672896 Study Design:: Simultaneous EEG, fMRI, CSF flow during sleep; n=11 healthy adults Key Findings:
- NREM slow waves drive CSF oscillations in human brain
- CSF flow occurs during slow-wave sleep, associated with arterial pulsation
- First direct evidence of sleep-dependent CSF pulsation in humansConclusion:: Sleep is associated with large, slow oscillations in cerebrospinal fluid that help clear waste products from the brain. Limitations:: Healthy controls only; not tested in disease populations. Small sample size (n=11). ME/CFS Relevance:: ME/CFS patients have disrupted sleep architecture; may impair CSF flow. Provides measurable physiological correlate of glymphatic activation. Establishes methodological framework for measuring glymphatic function in ME/CFS. Landmark study with multiple confirmations. Certainty: 0.90
9 Valdes-Hernandez et al. 2025 — Pain and Brain Clearance
Full Citation:: Valdes-Hernandez MC, Aguiar P, Maclntosh BJ, Hernandez MVM, Lyttelton O, Wardlaw JM, Bastin ME. Widespread and prolonged pain may reduce brain clearance. J Pain. 2025;26(8):1234–1245. (Valdes-Hernandez et al. 2025) DOI:: 10.1016/j.jpain.2025.00583 Study Design:: DTI-ALPS, pain assessment; sample size unclear from abstract Key Findings:
- Widespread prolonged pain associated with reduced brain clearance (DTI-ALPS)
- Suggests pain itself may impair glymphatic functionConclusion:: Widespread and prolonged pain may reduce brain clearance, potentially creating a vicious cycle. Limitations:: Abstract only; full details unavailable. Causality unclear. Certainty: 0.35
10 Louveau et al. 2015 — CNS Meningeal Lymphatic Vessels
Full Citation:: Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, Harris TH, Kipnis J. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015 Jul 16;523(7560):337–341. (Louveau et al. 2015) DOI:: 10.1038/nature14432 PMID:: 26030524 Study Design:: In vivo mouse; immunohistochemistry, light-sheet microscopy, CSF tracer injection, transgenic models Key Findings:
- Functional lymphatic vessels exist lining the dural sinuses in the CNS — previously thought absent
- CNS lymphatics capable of carrying fluid, immune cells (T cells), and macromolecules from CSF to deep cervical lymph nodes
- Vessels express PROX1, LYVE1, PODOPLANIN, VEGFR3, CCL21 — canonical lymphatic markers
- Vessels are continuous with meningeal arterial tree and exit along cranial nerves at skull baseConclusion:: The CNS is NOT immune-privileged in the way previously believed. It contains functional lymphatic vasculature that connects the brain to the peripheral immune system. This fundamentally revises neuroimmune doctrine. Limitations:: Mouse model only; initial discovery paper (now well-replicated); human meningeal lymphatics confirmed via Mestre 2022 (Nat Commun). ME/CFS Relevance:: Foundational anatomy. Without these vessels, neither glymphatic clearance to peripheral circulation nor skull-border B cell tolerance surveillance (Chayama et al. 2026) could function. Establishes the anatomic possibility of compartmentalized brain waste clearance and immune surveillance defects. Certainty: 0.85
11 Aspelund et al. 2015 — Dural Lymphatic Vascular System
Full Citation:: Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, Wiig H, Alitalo K. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med. 2015 Jun 29;212(7):991–999. (Aspelund et al. 2015) DOI:: 10.1084/jem.20142290 PMID:: 26077718 Study Design:: In vivo mouse; transgenic VEGF-C/D trap (K14-VEGFR3-Ig), whole-mount immunofluorescence, ISF tracer injection Key Findings:
- Dural lymphatic vessels absorb CSF from subarachnoid space and brain ISF via glymphatic system
- Fluid transport into deep cervical LNs via foramina at base of skull
- Transgenic mice with complete aplasia of dural lymphatic vessels showed attenuated macromolecule clearance and abrogated cervical LN transport
- Brain ISF pressure and water content were surprisingly unaffected — suggests compensatory mechanismsConclusion:: Dural lymphatic network provides the anatomic conduit for CSF→cervical LN drainage, essential for brain macromolecule clearance. Complementary and independent discovery to Louveau 2015. Limitations:: Mouse model only; ISF pressure compensation suggests parallel clearance routes; human functional confirmation pending. ME/CFS Relevance:: Demonstrates that disruption of dural lymphatics directly impairs brain waste clearance. If chronic neuroinflammation in ME/CFS damages or constricts these vessels (perivascular fibrosis, basement membrane thickening), it would create the anatomical substrate for glymphatic failure. Certainty: 0.80
12 Da Mesquita et al. 2018 — Meningeal Lymphatics in Ageing and Alzheimer’s
Full Citation:: Da Mesquita S, Louveau A, Vaccari A, Smirnov I, Cornelison RC, Kingsmore KM, Contarino C, Onengut-Gumuscu S, Farber E, Raper D, Viar KE, Powell RD, Baker W, Dabhi N, Bai R, Cao R, Hu S, Rich SS, Munson JM, Lopes MB, Overall CC, Acton ST, Kipnis J. Functional aspects of meningeal lymphatics in ageing and Alzheimer’s disease. Nature. 2018 Aug;560(7717):185–191. (Da Mesquita et al. 2018) DOI:: 10.1038/s41586-018-0368-8 PMID:: 30046111 Study Design:: In vivo mouse; meningeal lymphatic ablation via photodynamic or surgical disruption, VEGF-C rescue, Morris water maze, brain perfusion imaging Key Findings:
- Meningeal lymphatic dysfunction impairs paravascular CSF/ISF exchange and molecular clearance
- Lymphatic impairment induces cognitive dysfunction in wild-type mice
- Aged mice: meningeal lymphatic vessels narrower, less branched, reduced drainage capacity
- VEGF-C treatment in aged mice: restored meningeal lymphatic diameter and drainage, improved brain perfusion, rescued learning and memory
- AD transgenic mice (5xFAD, APP/PS1): lymphatic disruption aggravated meningeal and parenchymal amyloid-beta deposition
- Human AD tissue: meningeal amyloid-beta pathology resembling ablation phenotype in miceConclusion:: Meningeal lymphatic dysfunction is a modifiable risk factor for age-related cognitive decline and Alzheimer’s pathology. VEGF-C-mediated lymphatic rescue is a therapeutic avenue. The ageing-meningeal-lymphatic axis may be relevant to other conditions with neuroinflammatory and cognitive components. Limitations:: Mouse models with aggressive lymphatic ablation; mild human VEGF-C toxicity (lymphangiogenesis risk); human meningeal lymphatic function not directly measured; AD not ME/CFS. ME/CFS Relevance:: HIGH relevance via cross-disease extrapolation. Three parallels: (1) ME/CFS involves chronic neuroinflammation that may functionally mimic aged lymphatic dysfunction; (2) cognitive impairment (brain fog) is a core symptom; (3) if VEGF-C treatment can reverse cognitive impairment from meningeal lymphatic failure in mice, lymphatic-supporting interventions may merit investigation in ME/CFS. Human confirmation pending. Certainty: 0.80
13 Jiang-Xie et al. 2024 — Neuronal Dynamics Direct CSF Perfusion
Full Citation:: Jiang-Xie L-F, Drieu A, Bhasiin K, Quintero D, Smirnov I, Kipnis J. Neuronal dynamics direct cerebrospinal fluid perfusion and brain clearance. Nature. 2024 Mar;627(8002):157–164. (Jiang-Xie et al. 2024) DOI:: 10.1038/s41586-024-07108-6 PMID:: 38418877 Study Design:: In vivo mouse; multielectrode ISF recording, chemogenetic silencing (PSAM-hM4Di + uPSEM792), optogenetic wave synthesis (ChR2), DCE-MRI CSF infusion, tracer clearance assays Key Findings:
- Neuronal networks synchronize individual action potentials to create large-amplitude (100--500 μV), rhythmic (0.5--1.5 Hz) ionic waves in brain ISF
- Chemogenetic flattening of these waves largely impeded CSF infiltration into and molecular clearance from brain parenchyma
- Synthesized waves via transcranial optogenetic stimulation substantially potentiated CSF-to-ISF perfusion
- Neuronal activity — not vascular pulsatility or respiration — is the master driver of glymphatic perfusionConclusion:: Neurons are the master organizers of brain clearance. The fundamental principle: rhythmic neural synchrony → ionic waves → CSF perfusion → waste clearance. Introduces a new theoretical framework for macroscopic brain waves. Limitations:: Mouse model only (open-skull craniotomy for optogenetic stimulation limits human translation); anesthesia may alter neuronal dynamics; ion-sensitive electrodes measure ISF potassium — not direct CSF flow measurement; no disease model data. ME/CFS Relevance:: DIRECT relevance: ME/CFS involves documented sleep fragmentation, alpha-delta sleep (wake-like EEG intrusion into NREM), and dysautonomia — all conditions that would disrupt the rhythmic neural synchrony this paper identifies as the clearance pump. If neuronal synchrony is the master pump, sleep architecture failure in ME/CFS is not merely symptomatic but mechanistically causative of impaired waste clearance. This creates a plausible biological pathway: sleep fragmentation → disrupted neural oscillations → impaired ionic wave generation → reduced CSF perfusion → metabolic waste accumulation → cognitive symptoms + PEM amplification. Certainty: 0.78
14 Azcue et al. 2026 — GPCR Autoantibodies, Autonomic Dysfunction, and Cognition (0.55)
Full Citation:: Azcue N, Prada A, Del Pino R, et al. Involvement of autoantibodies against G protein-coupled receptors in post-COVID condition and Chronic Fatigue Syndrome. Sci Rep. 2026;16. DOI: 10.1038/s41598-026-49131-9. DOI:: 10.1038/s41598-026-49131-9 Published:: 2026-05-05 Study Design:: Case-control with comprehensive autonomic and cognitive testing Sample Size:: 59 ME/CFS, 96 PCC, 36 healthy controls Key Findings::
- ME/CFS patients had significantly higher beta2-adrenergic AAb titers vs PCC and HCs (F2,186=3.15, p=0.046)
- beta2 AAb correlated with sympathovagal imbalance in ME/CFS (r=0.45, p=0.001)
- M1, M3, M4 AAb titers positively correlated with verbal and working memory in ME/CFS
- PCC patients showed more borderline/pathological M3 muscarinic AAb results vs HCs
- beta2 AAb correlated with autonomic symptoms in PCC (r=0.27, p=0.048)
- Distinct AAb profiles suggest different immunological mechanisms between PCC and ME/CFSConclusion:: GPCR autoantibodies, particularly beta2-adrenergic and muscarinic receptor subtypes, are associated with autonomic dysfunction and cognitive performance in ME/CFS. Distinct profiles between PCC and ME/CFS suggest trigger-specific immunological trajectories. Limitations:: Moderate sample size. CellTrend ELISA specificity concerns (Vernino 2022 POTS null, Germain 2025 REAP/Luminex null). Cross-sectional design. Positive muscarinic-cognition correlation direction is counterintuitive. No functional validation of antibody activity. Not yet replicated. Certainty: 0.55 Research Stream:: gpcr-autoantibodies-azcue2026
15 Blaes et al. 2011 — GPCR Autoantibodies in Complex Regional Pain Syndrome (0.65)
Full Citation:: Blaes F, Wallukat G, et al. Autoimmunity against the beta2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. PAIN. 2011;152(12):2690-2700. DOI:: 10.1016/j.pain.2011.06.012 PMID:: 21816540 Published:: 2011 Study Design:: Case-control with functional cardiomyocyte bioassay Sample Size:: 20 CRPS patients, 10 healthy controls Key Findings::
- Functionally active autoantibodies against beta2-adrenergic and M2 muscarinic receptors identified in CRPS
- Antibodies show agonistic-like properties
- Bind to second extracellular loop of receptors
- Demonstrated functional activity in cellular assaysConclusion:: GPCR autoantibodies are functionally pathogenic in CRPS, providing mechanistic evidence that receptor-targeting autoantibodies can cause autonomic and sensory dysfunction. Relevant to ME/CFS as a parallel post-infectious/dysautonomic condition. Limitations:: Small sample size (n=20). CRPS not identical to ME/CFS — extrapolation requires caution. Functional assay limited to cardiovascular readout; CNS or cognitive effects not tested. Certainty: 0.65 Research Stream:: gpcr-autoantibodies-azcue2026
16 Sotzny et al. 2022 — GPCR Autoantibodies in Post-COVID Syndrome (0.60)
Full Citation:: Sotzny F, Filgueiras I, Kedor C, et al. Dysregulated Autoantibodies Targeting Vaso- and Immunoregulatory Receptors in Post Covid Syndrome Correlate with Symptom Severity. Front Immunol. 2022;13:981532. DOI:: 10.3389/fimmu.2022.981532 Published:: 2022 Study Design:: Observational case-control Sample Size:: Post-COVID syndrome patients (exact n not confirmed) Key Findings::
- Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in post-COVID syndrome
- Correlated with symptom severity
- Used CellTrend ELISA methodologyConclusion:: GPCR autoantibodies are present in post-COVID syndrome and correlate with symptom severity, extending the autoantibody hypothesis beyond classic ME/CFS to pandemic-associated post-infectious disease. Limitations:: CellTrend ELISA specificity concerns. Sample size unclear from available abstract data. Post-COVID syndrome heterogeneity. Certainty: 0.60 Research Stream:: gpcr-autoantibodies-azcue2026